Galenica to buy Relypsa to strengthen its unit Vifor Pharma
Thursday, July 21, 2016
Galenica will pay $32 per share in cash, or a total of approximately $1.53 billion. Galenica to acquire Relypsa to strengthen its business unit Vifor Pharma.
Vifor Pharma will gain a fully-integrated commercial organisation in the US and significantly strengthen its presence in the US cardio-renal market.
Source : reuters.com
